Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. [electronic resource]
Producer: 20180130Description: 309-315 p. digitalISSN:- 1742-7843
- Aged
- Antineoplastic Agents -- adverse effects
- Caffeine -- pharmacokinetics
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Chromatography, Liquid
- Cytochrome P-450 CYP1A2 -- genetics
- Cytochrome P-450 CYP3A -- genetics
- Dried Blood Spot Testing
- Drug Monitoring -- methods
- Erlotinib Hydrochloride -- adverse effects
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Midazolam -- pharmacokinetics
- Middle Aged
- Models, Biological
- Pharmacogenetics
- Pharmacogenomic Variants
- Phenotype
- Prospective Studies
- Protein Kinase Inhibitors -- adverse effects
- Substrate Specificity
- Tandem Mass Spectrometry
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.